Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 30 May 2024, regarding the commencement of the subscription
period in the partially underwritten rights issue (the "Rights Issue").
Teigland Eiendom AS has today exercised 2,623,948 subscription rights in the
Rights Issue. Please see the attached PDMR-forms related to the exercise of
subscription rights in the Rights Issue by a company closely associated with a
primary insiders in the Company.
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2024-06-04 17:30 CEST.